SV Investment Corporation is a Seoul-based venture capital and private equity firm founded in 2006. The firm invests across early, mid, and late venture stages as well as growth capital, primarily in technology, media, telecom, healthcare, and biotechnology sectors, having invested in over 220 companies with 48 successful IPOs.
Deal activity increased 50% year-over-year (3 deals in the last 12 months). Their most common stage is series-a (40% of deals). Average disclosed round size is $25.2M (across 42 rounds with reported amounts).
Portfolio
43
Fund Size
—
Top Stage
Series A
Last 12 Mo
3
Team
David Junghun bang
Managing Partner
Debra Peattie
Managing Partner
Gil Tae-ho
Managing Director
Hyo-Sang Lee
Executive Managing Director
JaeWon Lee
Leader / Managing Director
Ji-Hwa Yu
Executive Managing Director
MinGoo Kang
Leader / Managing Director
Park Ji Young
Managing Director
RyanJoowan Jung
Leader / Managing Director
TakKun Oh
Leader / Executive Managing Director
Seo Lee
Director
Hojin Kim
Principal
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 LinqAlpha | Series A | $22M | Jul 2026 |
 BreezeBio | Series B | — | Feb 2026 |
| BBreeze Bio | Series B | $60M | Jan 2026 |
| IInsera | Series A | — | Jan 2026 |
 XCENA | Series B | $135M | Jan 2026 |
 Pinetree Therapeutics, Inc. | Series B | $47M | Oct 2025 |
 Contoro Inc. | Series A | $12M | Mar 2025 |
 Cyclewell | Series A | — | Jan 2025 |
 MetisX | Series A | $44M | Aug 2024 |
| MetisX | Series A | $44M | May 2024 |
 Avelos Therapeutics | Series B | $12.3M | Apr 2024 |
 Aniai | Series A | $12M | Jan 2024 |
 MyRealTrip | Series F | — | Jan 2024 |
 Vedanta Biosciences | Series D | $40M | Jan 2024 |
| Avelos Therapeutics | Series A | $8M | Jan 2024 |
 Maka Motors | Seed | $37.6M | Jul 2023 |
 Maka Motors | Seed | $37.6M | Jul 2023 |
 Pyler | Series A | $16.9M | Jul 2023 |
| Contoro Inc. | Seed | $4.7M | Jun 2023 |
| Maka Motors | Seed | $37.6M | Jan 2023 |
| Maka Motors | Seed | $37.6M | Jan 2023 |
| Avelos Therapeutics | Series A | $8M | Aug 2022 |
 Rebellions | Series A | $22.8M | Jul 2022 |
 BoostImmune | Series A | — | Jun 2022 |
 List Biotherapeutics | Series A | $17.4M | Jan 2022 |
Top Co-Investors
Last updated: 7 October 2026